Prelude Capital Management’s Royalty Pharma RPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $966K | Buy |
26,812
+971
| +4% | +$35K | 0.09% | 266 |
|
|
2025
Q1 | $804K | Buy |
+25,841
| New | +$804K | 0.06% | 305 |
|
|
2024
Q2 | – | Sell |
-22,866
| Closed | -$694K | – | 1361 |
|
|
2024
Q1 | $694K | Buy |
+22,866
| New | +$694K | 0.04% | 442 |
|
|
2023
Q3 | – | Sell |
-15,944
| Closed | -$490K | – | 1192 |
|
|
2023
Q2 | $490K | Buy |
15,944
+944
| +6% | +$29K | 0.03% | 401 |
|
|
2023
Q1 | $540K | Hold |
15,000
| – | – | 0.03% | 387 |
|
|
2022
Q4 | $593K | Buy |
+15,000
| New | +$593K | 0.03% | 452 |
|
|
2022
Q2 | – | Sell |
-9,131
| Closed | -$356K | – | 1776 |
|
|
2022
Q1 | $356K | Buy |
+9,131
| New | +$356K | 0.01% | 793 |
|
|
2021
Q4 | – | Sell |
-6,560
| Closed | -$237K | – | 1863 |
|
|
2021
Q3 | $237K | Buy |
+6,560
| New | +$237K | 0.01% | 958 |
|